Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006;2(4):491-8.
doi: 10.2147/vhrm.2006.2.4.491.

Assessment of cognitive function in patients with essential hypertension treated with lercanidipine

J Tisaire-Sánchez  1 , J Roma, Ignacio Camacho-Azcargorta, J Bueno-Gómez, J Mora-Maciá, Angel Navarro
Affiliations
Clinical Trial

Assessment of cognitive function in patients with essential hypertension treated with lercanidipine

J Tisaire-Sánchez et al. Vasc Health Risk Manag. 2006.

Abstract

Objectives: The aim of this longitudinal, open-label, comparative, multicenter study was to assess cognitive function in hypertensive patients receiving mid-term treatment with lercanidipine.

Methods: Hypertensive patients aged 40 years or older were treated with lercanidipine (10 mg daily) after 7-10 days washout period. The duration of the study was 6 months. Blood pressure (BP) was measured every 4 weeks (JNC 6th report). In patients with inadequate BP control, doxazosin was added and up-titrated. At baseline and after 6 months of treatment, cognitive function was evaluated using the Spanish validated version of the Mini-Mental State Examination (MMSE) and the Trail Making Test (TMT).

Results: In the study population of 467 patients, BP decreased from 154.4/95.3 mmHg at baseline to 134.8/80.7 mmHg at 6 months. At the end of the study, 98% of patients were receiving lercanidipine, 20% an angiotensin-converting enzyme inhibitor, and 6% doxazosin. Adequate BP control was obtained in 68% of patients. The mean (standard deviation) MMSE scores improved from 32.35 (2.59) to 33.25 (2.36) (p < 0.0001). Patients with good BP control scored significantly better than those with inadequate BP control (p < 0.05), which was already observed at the first month.

Conclusions: The third-generation calcium channel antagonist, lercanidipine, improved cognitive function after 6 months of treatment especially in patients with good BP control, suggesting that improvements in cognitive function may be associated with a decrease in BP.

PubMed Disclaimer

References

    1. Ameiling EH, de Korte DH, Man in’t Veld A. Impact of diagnosis and treatment of hypertension on quality of life: a double-blind, randomized, placebo-controlled, cross-over study of beaxolol. J Cardiovasc Pharmacol. 1991;18:752–60. - PubMed
    1. American Heart Association. Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association; 1999. pp. 1–9.
    1. Applegate WB, Pressels S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the Elderly Program. Arch Intern Med. 1994;154:2154–60. - PubMed
    1. Bang LM, Chapman TM, Goa KL. Lercanidipine. A review of its efficacy in the management of hypertension. Drugs. 2003;63:2449–72. - PubMed
    1. Barrios V, Navarro A, Esteras A, et al. for the Investigators of ELYPSE Study Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Blood Press. 2002;11:95–100. - PubMed

MeSH terms